# INGENIUM Emilia Romagna

> INGENIUM Emilia Romagna is a VC fund backing Medical, Health Care and Privacy. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Sep 2015
- Lead investor: 60%
- Last updated: Aug 2026
- Website: http://www.meta-group.com/all-meta-projects/Pages/INGENIUM-Emilia-Romagna-I-Fund.aspx

INGENIUM Emilia Romagna is a VC fund focused on Medical and Health Care. INGENIUM Emilia Romagna was started with EUR 5.30 million by the Emilia Romagna region and EUR 1.7 million from fund managers. Managed by META Investment, the nine-year fund operated through the temporary acquisition of minority stakes in high-opportunity technological companies. It is now fully invested.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.1M–$2.2M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 60% |
| Health Care | 2 | 40% |
| Privacy | 1 | 20% |
| Security | 1 | 20% |
| Biopharma | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Angel | 1 | 20% |
| Funding Round | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GreenBone Ortho | GreenBone develops a wood-derived bone implants technology to generate biomimetic – reabsorbable– load bearing implant suitable to address non-union fractures. The idea was conceived and developed by a research group of ISTEC-CNR of Faenza comprised of Andrea Ruffini, Simone Sprio and Anna Tampieri. | $3.3M |  | Sep 23, 2015 |  |
| CellPly | Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing theability to monitor the clinical response to these treatments.Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions. | $2.2M | Seed | Mar 20, 2014 |  |
| Angiodroid | Angiodroid srl, a medical technology company, focuses on hemodynamics, vascular surgery, and interventional radiology. It offers an automatic injection system for carbon dioxide angiography. Its products include carbon dioxide injector that is used as a contrast medium for pheriperal interventional angiography; and a single use kit, which iscomposed of French catheters and a custom connection line. The company is based in San Lazzaro di Savena, Italy. | $2.1M | Seed | Oct 22, 2013 |  |
| Passpack | Users can make and store passwords in a single, organized list, then access them from anywhere leaving no traces behind on the computer. Secure collaboration features allow users to make, send, share or provision passwords to colleagues, clients and partners -- a secure alternative to spreadsheets in the workplace. Managed via a central onlinerepository.Passpack is a free, professional tool. Optional premium upgrades are available for the micro-small business sector. | $465K | Angel | May 16, 2008 |  |
| Intrauma | Intrauma was founded in 2006 and is based in Rivoli, near Turin, in Piedmont. The company designs and manufactures the O’nil range of locking plates, which has been in clinical use since 1998. Intrauma is committed to on-going research and development of both materials and manufacturing processes, in collaboration with experienced trauma surgeons,to provide the highest quality implants and to simplify today’s approach to Traumatology. Intrauma is also dedicated to building and maintaining strong customer relationships, believing that this is the foundation of a successful business.Intrauma TODAYToday, Intrauma is the second largest supplier of trauma devices in Italy, and is rapidly expanding its international sales and marketing operations across the world.This also gives the company the opportunity to work with surgeons across the globe, developing more unique products and continuing to improve traumatology techniques for the benefit of both patient and surgeon. | $2.2M | Series A | Jan 01, 2008 |  |

5 of 5 investments shown.

## Co-investors
- [Italian Angels for Growth](https://shizune.co/investors/profile/italian-angels-for-growth) — VC Fund, 4 deals together
- [Embed Capital](https://shizune.co/investors/profile/embed-capital) — VC Fund, 1 deal together
- [Indaco Venture Partners](https://shizune.co/investors/profile/indaco-venture-partners) — VC Fund, 1 deal together
- [Sistema Investimenti](https://shizune.co/investors/profile/sistema-investimenti) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Italy](https://shizune.co/investors/medical-vc-funds-italy)
- [Biotechnology Investors in Italy](https://shizune.co/investors/biotechnology-investors-italy)
- [Biotechnology VC Funds in Italy](https://shizune.co/investors/biotechnology-vc-funds-italy)
- [Health Care VC Funds in Italy](https://shizune.co/investors/health-care-vc-funds-italy)
- [Biotech Investors in Italy](https://shizune.co/investors/biotech-investors-italy)
- [Biotech VC Funds in Italy](https://shizune.co/investors/biotech-vc-funds-italy)

## FAQ

### What does INGENIUM Emilia Romagna invest in?

INGENIUM Emilia Romagna invests primarily in Medical, Health Care and Privacy startups, most often at Seed and Angel stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is INGENIUM Emilia Romagna's check size?

INGENIUM Emilia Romagna typically joins rounds of $2.1M–$2.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds INGENIUM Emilia Romagna participates in.

### When did INGENIUM Emilia Romagna last invest?

The most recent investment recorded for INGENIUM Emilia Romagna closed in Sep 2015. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co